Effects of SB 217242, a non-selective endothelin (ET)-A and ET-B receptor antagonist, in healthy humans.

被引：0
|
作者：
Freed, MI
Thompson, KA
Wilson, DE
Ohlstein, EH
Dennis, M
Jorkasky, DK
机构：
[1] SMITHKLINE BEECHAM PHARMACEUT, DEPT CLIN PHARMACOL, PHILADELPHIA, PA USA
[2] SMITHKLINE BEECHAM PHARMACEUT, DEPT CARDIOVASC PHARMACOL, PHILADELPHIA, PA USA
[3] SMITHKLINE BEECHAM PHARMACEUT, DEPT DRUG METAB & PHARMACOKINET, PHILADELPHIA, PA USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 1996年 / 7卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A1558 / A1558
页数：1
相关论文
共 50 条
  • [1] Performance-enhancing effects of non-selective endothelin receptor antagonist
    Ostojic, Sergej M.
    Stojanovic, Marko
    Calleja-Gonzalez, Julio
    Olcina, Guillermo
    Sekulic, Damir
    Hoffman, Jay R.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 171 (02) : 294 - 297
  • [2] Cardiopulmonary protective effects of ET-B receptor antagonism during ET-B activation in vivo.
    Rasmussen, TE
    Jougasaki, M
    Supaporn, T
    Hallett, JW
    Brooks, DP
    Burnett, JC
    CIRCULATION, 1996, 94 (08) : 14 - 14
  • [3] Effects of selective and non-selective endothelin receptor blockade on ET-1-induced pressor response in the hamster
    Honoré, JC
    Fecteau, MH
    Wessale, JL
    D'Orléans-Juste, P
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2004, 44 : S68 - S71
  • [4] Effects of selective endothelin (ET)-A receptor antagonist versus dual ET-A/B receptor antagonist on hearts of streptozotocin-treated diabetic rats
    Miyauchi, Yumi
    Jesmin, Subrina
    Sakai, Satoshi
    Kamiyama, Junko
    Shimojo, Nobutake
    Rahman, Arifur
    Islam, Majedul
    Zaedi, Sohel
    Maeda, Seiji
    Maruyama, Hidekazu
    Mizutani, Taro
    Homma, Satoshi
    Aonuma, Kazutaka
    Miyauchi, Takashi
    LIFE SCIENCES, 2014, 111 (1-2) : 6 - 11
  • [5] ROLE OF ENDOTHELIN RECEPTOR SUBTYPE-B (ET-B) IN MYOCARDIAL-ISCHEMIA
    SARGENT, CA
    LIU, ECK
    CHAO, CC
    WEBB, ML
    GROVER, GJ
    LIFE SCIENCES, 1994, 55 (23) : 1833 - 1844
  • [6] PHEOPHORBIDE A, A POTENT ENDOTHELIN RECEPTOR ANTAGONIST FOR BOTH ET(A) AND ET(B) SUBTYPES
    OHSHIMA, T
    HIRATA, M
    ODA, T
    SASAKI, A
    SHIRATSUCHI, M
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1994, 42 (10) : 2174 - 2176
  • [7] BQ-123, A SELECTIVE ENDOTHELIN ET(A) RECEPTOR ANTAGONIST
    MORELAND, S
    CARDIOVASCULAR DRUG REVIEWS, 1994, 12 (01): : 48 - 69
  • [8] Beneficial hemodynamic effects of bosentan, an ET(A) and ET(B) receptor antagonist of endothelin in portal hypertension.
    Lebrec, D
    Cailmail, S
    Moreau, R
    Gadano, A
    Clozel, M
    HEPATOLOGY, 1996, 24 (04) : 759 - 759
  • [9] IRL 2500: A potent ET(B) selective endothelin antagonist
    Fruh, T
    Saika, H
    Svensson, L
    Pitterna, T
    Sakaki, J
    Okada, T
    Urade, Y
    Oda, K
    Fujitani, Y
    Takimoto, M
    Yamamura, T
    Inui, T
    Makatani, M
    Takai, M
    Umemura, I
    Teno, N
    Toh, H
    Hayakawa, K
    Murata, T
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (19) : 2323 - 2328
  • [10] Endothelin (ET) receptor antagonism does not alter renal hemodynamic responses or urinary sodium excretion in healthy humans.
    Freed, MI
    Thompson, KA
    Wilson, DE
    Etheredge, R
    Jorkasky, DK
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A1657 - A1657
12345